Pavel Hamet

Montréal-based BioCapital Investment Advisors, Inc. manages the BioCapital health technology mutual fund family.

Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada.

Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada.

AGC Biologics SpA engages in the research, development, manufacturing, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. Its approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. It also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trial activities. The company was founded by Claudio Bordignon on July 11, 1996 and is headquartered in Milan, Italy.

The Canadian Institutes of Health Research is the federal health research financing organization in Canada. The non-profit company is based in Ottawa, Canada. The organization's main focus is to fund health research projects across the country.

Société de développement Angus engages in real estate developments. It specializes in concept development and planning, legal and financial engineering services, acquisition of land and buildings, and marketing, leasing and sales of developed spaces. The company was founded by Christian Yaccarini in 1995 and is headquartered in Montreal, Canada.